AU2020403443B2 - New methylquinazolinone derivatives - Google Patents

New methylquinazolinone derivatives Download PDF

Info

Publication number
AU2020403443B2
AU2020403443B2 AU2020403443A AU2020403443A AU2020403443B2 AU 2020403443 B2 AU2020403443 B2 AU 2020403443B2 AU 2020403443 A AU2020403443 A AU 2020403443A AU 2020403443 A AU2020403443 A AU 2020403443A AU 2020403443 B2 AU2020403443 B2 AU 2020403443B2
Authority
AU
Australia
Prior art keywords
compound
formula
cancer
treatment
braf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020403443A
Other languages
English (en)
Other versions
AU2020403443A1 (en
Inventor
Cosimo Dolente
David Stephen HEWINGS
Daniel Hunziker
Daniela Krummenacher
Piergiorgio Francesco Tommaso PETTAZZONI
Juergen Wichmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2020403443A1 publication Critical patent/AU2020403443A1/en
Application granted granted Critical
Publication of AU2020403443B2 publication Critical patent/AU2020403443B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Harvester Elements (AREA)
  • Combines (AREA)
AU2020403443A 2019-12-10 2020-12-08 New methylquinazolinone derivatives Active AU2020403443B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214941.7 2019-12-10
EP19214941 2019-12-10
PCT/EP2020/084976 WO2021116055A1 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Publications (2)

Publication Number Publication Date
AU2020403443A1 AU2020403443A1 (en) 2022-05-12
AU2020403443B2 true AU2020403443B2 (en) 2023-02-23

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020403443A Active AU2020403443B2 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Country Status (29)

Country Link
US (2) US12116349B2 (enExample)
EP (2) EP4483882A3 (enExample)
JP (2) JP7108146B2 (enExample)
KR (1) KR102836833B1 (enExample)
CN (2) CN114787156B (enExample)
AR (1) AR122351A1 (enExample)
AU (1) AU2020403443B2 (enExample)
CL (1) CL2022001529A1 (enExample)
CO (1) CO2022008968A2 (enExample)
CR (1) CR20220251A (enExample)
DK (1) DK4073065T3 (enExample)
ES (1) ES3023264T3 (enExample)
FI (1) FI4073065T3 (enExample)
HR (1) HRP20250418T1 (enExample)
HU (1) HUE071148T2 (enExample)
IL (2) IL316473A (enExample)
LT (1) LT4073065T (enExample)
MA (1) MA58087B1 (enExample)
MX (1) MX2022006783A (enExample)
PE (1) PE20221778A1 (enExample)
PH (1) PH12022551119A1 (enExample)
PL (1) PL4073065T3 (enExample)
PT (1) PT4073065T (enExample)
RS (1) RS66721B1 (enExample)
SI (1) SI4073065T1 (enExample)
TW (2) TWI877268B (enExample)
UA (1) UA128299C2 (enExample)
WO (1) WO2021116055A1 (enExample)
ZA (2) ZA202204675B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158541A1 (en) * 2019-12-10 2021-06-17 Cosimo Dolente New braf inhibitors as paradox breakers
SI4073065T1 (sl) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
MX2022015703A (es) 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
IL308015A (en) * 2021-06-09 2023-12-01 Hoffmann La Roche Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
CN117642166A (zh) * 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
JP2024522603A (ja) * 2021-06-09 2024-06-21 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト （３ｒ）－ｎ－［２－シアノ－４－フルオロ－３－（３－メチル－４－オキソ－キナゾリン－６－イル）オキシ－フェニル］－３－フルオロ－ピロリジン－１－スルホンアミドの新規固形物
EP4378478A4 (en) 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
IL312171A (en) 2021-11-04 2024-06-01 Hoffmann La Roche Innovative use of the quinazolinone compound for cancer treatment
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
JP2025537786A (ja) 2022-11-18 2025-11-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 進行性固形がんまたは転移の治療のためのｂｒａｆ阻害剤としてのキナゾリノン化合物
EP4634171A1 (en) * 2022-12-15 2025-10-22 F. Hoffmann-La Roche AG Process for the preparation of a quinazolinone derivative
JP2025541200A (ja) * 2022-12-15 2025-12-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん処置のための併用療法
IL324898A (en) 2023-07-04 2026-01-01 Hoffmann La Roche New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinozolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
WO2025108405A1 (zh) 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
WO2025153057A1 (zh) 2024-01-17 2025-07-24 海思科医药集团股份有限公司 一种含braf抑制剂的药物组合物及其在医药上的应用
WO2026037755A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives
WO2026046946A1 (en) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
AU2009226136B2 (en) 2008-03-17 2013-08-15 Ambit Biosciences Corporation Quinazoline derivatives as RAF kinase modulators and methods of use thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
CA2882410A1 (en) 2012-09-19 2014-03-27 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
BR112017025045A2 (pt) 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
PL3359541T3 (pl) 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
SI4073065T1 (sl) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
CA3158541A1 (en) * 2019-12-10 2021-06-17 Cosimo Dolente New braf inhibitors as paradox breakers
MX2022015703A (es) 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
CN118561841A (zh) 2020-12-18 2024-08-30 豪夫迈·罗氏有限公司 新的芳基-吡啶并-嘧啶-酮衍生物
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
KR20240115893A (ko) 2021-12-08 2024-07-26 어레이 바이오파마 인크. N-(2-클로로-3-((5-클로로-3-메틸-4-옥소-3,4-다이하이드로퀴나졸린-6-일)아미노)-4-플루오로페닐)-3-플루오로아제티딘-1-설폰아미드의결정질 형태

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WENGLOWSKY STEVE; REN LI; GRINA JONAS; HANSEN JOSHUA D.; LAIRD ELLEN R.; MORENO DAVID; DINKEL VICTORIA; GLOOR SUSAN L.; HASTINGS G: "Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600Ekinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 24, no. 8, 13 March 2014 (2014-03-13), Amsterdam NL , pages 1923 - 1927, XP028841756, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2014.03.007 *

Also Published As

Publication number Publication date
CN114787156B (zh) 2024-07-26
EP4073065B1 (en) 2025-02-19
BR112022011123A2 (pt) 2022-08-23
LT4073065T (lt) 2025-04-25
MA58087B1 (fr) 2025-04-30
CN118791472A (zh) 2024-10-18
PH12022551119A1 (en) 2023-08-23
TW202136245A (zh) 2021-10-01
JP7108146B2 (ja) 2022-07-27
ZA202204675B (en) 2022-12-21
HRP20250418T1 (hr) 2025-06-06
AU2020403443A1 (en) 2022-05-12
SI4073065T1 (sl) 2025-06-30
US20240174621A1 (en) 2024-05-30
KR102836833B1 (ko) 2025-07-22
KR20220110554A (ko) 2022-08-08
PE20221778A1 (es) 2022-11-16
EP4483882A3 (en) 2025-03-05
ES3023264T3 (en) 2025-05-30
IL316473A (en) 2024-12-01
PT4073065T (pt) 2025-04-15
HUE071148T2 (hu) 2025-08-28
IL292161A (en) 2022-06-01
RS66721B1 (sr) 2025-05-30
MX2022006783A (es) 2022-07-11
CL2022001529A1 (es) 2023-02-10
PL4073065T3 (pl) 2025-05-19
US20220298119A1 (en) 2022-09-22
IL292161B2 (en) 2025-04-01
EP4483882A2 (en) 2025-01-01
FI4073065T3 (fi) 2025-04-16
AR122351A1 (es) 2022-09-07
TWI877268B (zh) 2025-03-21
WO2021116055A1 (en) 2021-06-17
CA3162883A1 (en) 2021-06-17
NZ787393A (en) 2025-07-25
ZA202206923B (en) 2024-10-30
CR20220251A (es) 2022-07-11
US12116349B2 (en) 2024-10-15
CN114787156A (zh) 2022-07-22
IL292161B1 (en) 2024-12-01
DK4073065T3 (da) 2025-04-22
TW202504895A (zh) 2025-02-01
EP4073065A1 (en) 2022-10-19
TWI908405B (zh) 2025-12-11
JP7802514B2 (ja) 2026-01-20
JP2022531609A (ja) 2022-07-07
UA128299C2 (uk) 2024-05-29
CO2022008968A2 (es) 2022-07-19
JP2022124458A (ja) 2022-08-25

Similar Documents

Publication Publication Date Title
EP4073065B1 (en) New methylquinazolinone derivatives
CN113966335B (zh) 用于治疗癌症的egfr抑制剂
US20240139192A1 (en) Methods and compositions comprising a braf inhibitor and a mek inhibitor
EA025322B1 (ru) Производные дигидробензооксазина и дигидропиридооксазина
WO2025096856A1 (en) Covalent cereblon ligands
CA3162883C (en) (3r)-and (3s)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide compounds and their use as braf inhibitors
RU2802968C1 (ru) Новые производные метилхиназолинона
HK40113036A (en) New methylquinazolinone derivatives
HK40074142B (en) New methylquinazolinone derivatives
HK40074142A (en) New methylquinazolinone derivatives
BR112022011123B1 (pt) Composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto
RU2818677C2 (ru) Ингибитор egfr для лечения рака
TW202615030A (zh) 新穎甲基喹唑啉酮衍生物
BR122024014190A2 (pt) Combinação, uso de um inibidor de braf e um inibidor de mek, composições farmacêuticas e uso da composição farmacêutica
HK40063822A (en) Egfr inhibitor for the treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)